Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer: Data of a Pooled Analysis
- PMID: 30896526
- DOI: 10.1097/PPO.0000000000000358
Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer: Data of a Pooled Analysis
Abstract
Purpose: Improvements in systemic treatment have led to a prolongation of survival and quality of life in patients with metastatic tumors in recent years. However, despite this improved standard of care, it is expected that the progression-free survival (PFS) for patients with refractory cancers will continue to decline over subsequent therapy lines. In those patients, studies and meta-analyses showed that treatment based on multiplatform molecular profiling (MMP) of tumor tissue may derive a clinical benefit. The aim of this study was to analyze if molecular-based therapy may prolong PFS compared with the PFS of the immediately prior therapy.
Methods: We pooled clinical data of 140 patients treated within 3 recently conducted pilot studies and included an additional 21 patients who were treated within the ongoing ONCO-T-PROFILE program. The PFS of the molecular-based treatment was compared with the PFS of the previous therapy using Kaplan-Meier curves.
Results: In heavily pretreated cancer patients, the PFS could be significantly improved using molecular-based treatment options (120.0 vs. 89.5 days). More than 50% of patients showed a clinical benefit from MMP-guided therapy as defined by a PFS ratio of 1.3 or greater.
Conclusions: We conclude that pretreated cancer patients can benefit from incorporation of molecular profiling, as demonstrated by not only an increase of the PFS ratio but also PFS. Further randomized trials in specific tumor subtypes may help establish specific patient populations who might benefit most from MMP guidance.
Comment in
-
Multiplatform Molecular Profiling: A Precision Medicine Victory Built on Cytotoxic Chemotherapy.Cancer J. 2019 Mar/Apr;25(2):80. doi: 10.1097/PPO.0000000000000359. Cancer J. 2019. PMID: 30896527 Free PMC article. No abstract available.
Similar articles
-
Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.Bull Cancer. 2020 Apr;107(4):410-416. doi: 10.1016/j.bulcan.2019.12.010. Epub 2020 Mar 4. Bull Cancer. 2020. PMID: 32145962
-
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.Oncotarget. 2016 Aug 30;7(35):56491-56500. doi: 10.18632/oncotarget.10606. Oncotarget. 2016. PMID: 27447854 Free PMC article.
-
Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.Genes Cancer. 2016 Sep;7(9-10):301-308. doi: 10.18632/genesandcancer.121. Genes Cancer. 2016. PMID: 28050231 Free PMC article.
-
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008941. doi: 10.1002/14651858.CD008941.pub2. Cochrane Database Syst Rev. 2012. PMID: 22786517 Review.
-
Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2019 Jan;37(1):19-27. doi: 10.1007/s40273-018-0689-3. Pharmacoeconomics. 2019. PMID: 30030817 Review.
Cited by
-
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.JCO Precis Oncol. 2023 Apr;7:e2200421. doi: 10.1200/PO.22.00421. JCO Precis Oncol. 2023. PMID: 37053535 Free PMC article.
-
The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives.Gynecol Oncol Rep. 2022 Jun 28;42:101035. doi: 10.1016/j.gore.2022.101035. eCollection 2022 Aug. Gynecol Oncol Rep. 2022. PMID: 35898197 Free PMC article.
-
Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?J Natl Cancer Inst. 2020 Aug 1;112(8):773-778. doi: 10.1093/jnci/djz240. J Natl Cancer Inst. 2020. PMID: 31868907 Free PMC article.
-
Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment.Cost Eff Resour Alloc. 2019 Oct 21;17:23. doi: 10.1186/s12962-019-0191-6. eCollection 2019. Cost Eff Resour Alloc. 2019. PMID: 31641338 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical